DWA
PRQR icon

Dorsey Wright & Associates’s ProQR Therapeutics PRQR Stock Holding History

Dorsey Wright & Associates’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,860
Closed -$55K – 338
2021
Q4 		$55K Buy
+6,860
New +$52.2K 0.01% 224
2019
Q1 		– Sell
-960
Closed -$15K – 317
2018
Q4 		$15K Buy
+960
New +$17.6K ﹤0.01% 198

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dorsey Wright & Associates's PRQR Position: Q1 2022 in Review

Dorsey Wright & Associates sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 6,860 shares — an estimated $55K sold.

Dorsey Wright & Associates first reported a position in PRQR in Q4 2018 and held it in 2 quarters. The position peaked at $55K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • Dorsey Wright & Associates reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dorsey Wright & Associates sold 6,860 ProQR Therapeutics shares in Q1 2022, an estimated $55K.
  • Dorsey Wright & Associates first reported a position in ProQR Therapeutics in Q4 2018 and held it in 2 quarters.
  • Dorsey Wright & Associates's ProQR Therapeutics position peaked at $55K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Dorsey Wright & Associates's 13F filing for Q1 2022, filed 27 Apr 2022.